Nanosonics, an Australian medical device company specialising in infection prevention, has launched an upgraded version of its Trophon ultrasound probe sterilising device in the United Kingdom and Europe. The company focuses on the development and commercialisation of innovative infection control and decontamination products and services. A regulatory application for the upgraded device has also been submitted to the United States Food and Drug Administration (FDA).
In addition to the hardware upgrade, Nanosonics has also released a new software upgrade for its existing range of products. This software update aims to improve the efficiency and effectiveness of the sterilisation process, providing enhanced benefits to healthcare providers.
The market has responded positively to the news, with Nanosonics shares experiencing a boost. Following the announcement, Nanosonics shares rose by 4 per cent on the Australian Securities Exchange.
Industry analysts have noted that there is a substantial opportunity for upgrade sales. However, they also cautioned that many hospitals in the United States are currently facing financial constraints, which may potentially impact the adoption rate of the new Trophon device in that market.
